AI-Discovered Peptide BRP Shows Potential for Obesity Treatment with Reduced Side Effects
Introduction
Researchers at Stanford Medicine have identified a naturally occurring molecule, designated BRP, which suppresses appetite by acting directly on the brain''s hypothalamus. The discovery, facilitated by an artificial intelligence tool, may lead to new obesity treatments that avoid the gastrointestinal side effects associated with current GLP-1 receptor agonist drugs such as Ozempic, Wegovy, and Mounjaro.
Main Body
The molecule BRP is a 12-amino-acid peptide that was isolated using a custom AI system called Peptide Predictor. This tool scanned approximately 20,000 human genes and identified 2,683 candidate hormone-like peptides, from which the Stanford team selected about 100 for testing. BRP emerged as the most effective in reducing weight in obese mice, which lost weight after daily injections while untreated controls gained weight. Katrin Svensson, the senior author of the study, has co-founded a company to initiate human clinical trials in the near future. Current weight-loss injections mimic the hormone GLP-1, which acts on multiple body systems to suppress appetite. However, their primary mechanism involves the hindbrain, which generates sensations of fullness and, in many patients, leads to nausea, vomiting, diarrhea, abdominal pain, and constipation. Giles Yeo, professor of molecular neuroendocrinology at the UK Medical Research Council''s Metabolic Diseases Unit, explained that the hindbrain targets visceral effects such as uncomfortable fullness, whereas the hypothalamus functions as a hunger sensor that detects energy deficit. BRP appears to act exclusively on the hypothalamus, potentially reducing appetite without inducing the unpleasant fullness that causes nausea. Additionally, animal trials indicated that BRP promoted fat loss without muscle loss, a side effect sometimes observed with GLP-1 mimics. Randy J. Seeley, professor of surgery at the University of Michigan, praised the scale of the peptide screening but cautioned that success in animal models does not guarantee efficacy or safety in humans. He noted that obesity is a chronic condition requiring long-term treatment, so any new drug must demonstrate a high safety profile for prolonged use. GLP-1-based drugs, which are modified versions of natural hormones engineered to last longer in the body, also offer cardiovascular benefits beyond weight loss. BRP could similarly be modified for extended activity. Yeo emphasized that additional treatment options are critical given the global obesity crisis, with approximately one billion people affected and obesity now causing more deaths than famine. He stated that having a variety of tools increases the likelihood that patients will find a sustainable regimen and maintain weight loss.
Conclusion
The discovery of BRP represents a potential advancement in obesity pharmacotherapy, offering a mechanism that may circumvent the nausea associated with current GLP-1 agonists. However, its clinical utility remains contingent on successful human trials and long-term safety assessments. Even if approved, BRP is expected to complement rather than replace existing treatments, as GLP-1 drugs provide additional health benefits. The use of AI to identify novel peptides marks a methodological innovation that could accelerate future drug development.